Targeted therapies in the management of metastatic bladder cancer
Authors Matteo Fassan, Edouard J Trabulsi, Leonard G Gomella, Raffaele Baffa
Published 15 February 2008 Volume 2007:1(4) Pages 393—406
Matteo Fassan, Edouard J Trabulsi, Leonard G Gomella, Raffaele Baffa
Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
Abstract: The management of metastatic urothelial carcinoma (UC) of the bladder is a common and complex clinical challenge. Despite the fact that UC is one of the most frequent tumors in the population, long term survival for metastatic disease remains low, and chemotherapy is curative for only a small minority of patients. UC is genetically heterogeneous, and it is surrounded by a complex tissue microenvironment. The problems of clinical practice in the field of metastatic bladder cancer have begun to stimulate translational research. Advances in the understanding of the molecular biology of urothelial cancer continue to contribute to the identification of molecular pathways upon which new therapeutic approaches can be targeted. New agents and strategies have recently been developed which can direct the most appropriate choice of treatment for advanced disease. A review of literature published on the targeted therapy for metastatic bladder cancer is presented, focusing on the molecular pathways shut down by the new therapeutic agents.
Keywords: bladder cancer, metastasis, gene targeting, gene therapy, molecular biology